Awakn Advances AUD Treatment Trial, Completes MDMA Feasibility Study

Awakn partnered with Orphan Insight Ltd., which provides consulting on bringing novel drug therapies to market.

Toronto-based Awakn Life Sciences Corp. (OTC: AWKNF) received approval for a Phase III clinical trial in the United Kingdom for its lead treatment candidate, AWKN-P001, targeting severe alcohol use disorder.

According to a statement, U.K.’s Medicines and Healthcare Products Regulatory Agency and the Health Research Authority approved the trial, with funding support from both Awakn and the National Institute for Health Research Efficacy and Mechanism Evaluation Programme. According to previous reporting, the U.K. government will cover most of the trial costs, leaving Awakn to contribute only $1.25 million.

Awakn also said it completed a feasibility study for a proprietary formulation of MDMA, using Catalent‘s Zydis orally disintegrating tablet technology, which the company has high hopes for. That study assessed the stability of MDMA in the new delivery format, which could offer an alternative method of administration for such treatments and shorten therapy sessions.

To address market access, Awakn said it partnered with Orphan Insight Ltd., which provides consulting on bringing novel drug therapies to market. The two will collaborate on developing strategies to “advance market access, pricing, and reimbursement” for AWKN-P001 in various key markets, including the U.S. and several European countries.

The company also embarked on a non-brokered private placement financing in April 2023, initially seeking to raise $3 million, which was later increased to $4 million.

The latest tranche of that financing raised $230,000, bringing the total to $2.96 million.

The completion of the offering is subject to receiving the necessary corporate and regulatory approvals, including approval from the NEO Exchange.

Adam Jackson

Adam Jackson writes about the cannabis industry for the Green Market Report. He previously covered the Missouri Statehouse for the Columbia Missourian and has written for the Missouri Independent. He most recently covered retail, restaurants and other consumer companies for Bloomberg Business News. You can find him on Twitter at @adam_sjackson and email him at adam.jackson@crain.com.


Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.